Truenat MTB Ultima 在 HIV 高流行区诊断肺结核的准确性
在南非开普敦 498 例疑似肺结核成人中评估 Truenat MTB Ultima(Ultima)与 MTB Plus、Xpert MTB/RIF Ultra(Ultra)的诊断准确性。Ultima 的 TB 敏感度为 90%(85,93),特异度为 85%(80,88);MTB Plus 敏感度 84%(78,88)、特异度 95%(92,97),Ultra 敏感度 92%(87,95)、特异度 95%(92,97)。Ultima 达到 WHO 最低敏感度推荐,但特异度、试剂批间变异及无效结果欠佳。
要点
- Ultima 的敏感度 90%(85,93)达到 WHO 最低推荐,但特异度 85%(80,88)低于 MTB Plus 和 Ultra 的 95%。
- Ultima 无效结果占 14%(11,16),MTB Plus 占 20%(17,23),至少一半经同洗脱液复测解决。
- MTB-RIF Dx 在 DNA 提取当天与提取后检测的无效结果率分别为 18%(10,26)与 44%(35,51)(Ultima 阳性洗脱液)。
核心结论
- Ultima 的 TB 敏感度 90%(85,93)达到 WHO 最低推荐,但特异度 85%(80,88)欠佳。
- Ultima 和 MTB Plus 的无效结果率分别为 14%(11,16)和 20%(17,23)。
- MTB-RIF Dx 的无效结果率在提取当天与提取后检测间存在差异,且存在试剂批间变异。
研究设计与样本
- 前瞻性诊断准确性研究,纳入南非开普敦基层诊所自就诊的疑似肺结核成人(≥18 岁,n=498),采样时间 2016-02-19 至 2023-02-22。
- 微生物学参考标准为单次培养诊断 TB,对分离株行 MTBDRplus 检测判定利福平敏感性。
- 54%(n=269)的参与者有 HIV,42%(n=210)有既往 TB。
主要发现
- Ultima、MTB Plus、Ultra 的 TB 敏感度分别为 90%(85,93)、84%(78,88)、92%(87,95),特异度分别为 85%(80,88)、95%(92,97)、95%(92,97)。
- Ultima 和 MTB Plus 的无效结果率分别为 14%(11,16)和 20%(17,23),至少一半经同洗脱液复测解决。
- MTB-RIF Dx 在 DNA 提取当天与提取后检测的无效结果率:Ultima 阳性洗脱液为 18%(10,26)vs 44%(35,51),MTB Plus 阳性洗脱液为 9%(3,16)vs 27%(18,35)。
- 对 Ultima 或 MTB Plus 报告「very low」半定量类别的样本,当天利福平药敏检测的无效结果率分别为 75%(65,86)和 73%(58,89)。
临床怎么用
- Ultima 可用于肺结核检测且敏感度达到 WHO 最低推荐,但需注意其特异度低于 MTB Plus 和 Ultra。
- MTB-RIF Dx 宜在 DNA 提取当天进行以降低无效结果率,尤其对「very low」半定量样本。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Assess Truenat MTB Ultima (Ultima) diagnostic accuracy, alongside standard-of-care Truenat MTB Plus (MTB Plus) and Xpert MTB/RIF Ultra (Ultra) tests, for pulmonary tuberculosis (TB) diagnosis in a high-burden setting. We secondarily evaluated Truenat MTB-RIF Dx (MTB-RIF Dx) on Ultima- or MTB Plus-positive samples for rifampicin susceptibility diagnosis. METHODS: Adults (≥18 years; n = 498) with presumptive TB self-presenting to primary care clinics in Cape Town, South Africa (19/02/2016-22/02/2023) provided sputa. The microbiological reference standard was a single culture for TB and MTBDRplus on an isolate for rifampicin susceptibility. RESULTS: In total, 54% (n = 269) of the participants had HIV, and 42% (n = 210) had previous TB. The proportion of Ultima and MTB Plus unsuccessful results was 14% (95% CI 11, 16) and 20% (17, 23), respectively, with at least half resolving upon retesting the same eluate. In a three-way analysis, Ultima, MTB Plus, and Ultra had TB sensitivities of 90% (85, 93), 84% (78, 88), and 92% (87, 95) and specificities of 85% (80, 88), 95% (92, 97), and 95% (92, 97). Ultima specificity did not improve with Ultra in the reference standard. MTB-RIF Dx had high unsuccessful result rates that varied if done on the day of DNA extraction or on Ultima- [18% (10, 26) vs. 44% (35, 51) if after day of extraction] or MTB Plus-positive eluates [9% (3, 16) vs. 27% (18, 35)]. Same day rifampicin susceptibility testing was often unsuccessful in samples with the "very low" semiquantitation category reported by Ultima [75% (65, 86)] or MTB Plus [73% (58, 89)] but had 100% (40, 100) sensitivity and 99% (96, 100) specificity (on both MTB Plus- or Ultima-positive DNA). Reagent lot variation in unsuccessful and false positive results was observed. DISCUSSION: Ultima met the minimum sensitivity recommended by the WHO for TB detection, but specificity, reagent lot variation, and unsuccessful results were suboptimal.
引用
- Abdulgader SM, Chiwaya AM, Nwamba WV, et al. Diagnostic accuracy of Truenat MTB Ultima on sputum for pulmonary tuberculosis diagnosis in an HIV-endemic setting. Clin Microbiol Infect. 2025. PMID: 40254059. doi:10.1016/j.cmi.2025.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。